Equitable global allocation of monkeypox vaccines.

Publication date: Jul 15, 2023

With the world grappling with continued spread of monkeypox internationally, vaccines play a crucial role in mitigating the harms from infection and preventing spread. However, countries with the greatest need – particularly historically endemic countries with the highest monkeypox case-fatality rates – are not able to acquire scarce vaccines. This is unjust, and requires rectification through equitable allocation of vaccines globally. We propose applying the Fair Priority Model for such allocation, which emphasizes three key principles: 1) preventing harm; 2) prioritizing the disadvantaged; and 3) treating people with equal moral concern. Post-exposure prophylaxis (PEPV) has the most potential to mitigate harm, and so ensuring countries have sufficient supply for PEPV should be the first priority. And historically endemic countries, which face disadvantages that compound potential harms from monkeypox, should be the first recipients of such vaccines. Once sufficient supply is allocated for countries to apply PEPV, global allocation could move on to pre-exposure prophylaxis (PrEP), again prioritizing historically endemic countries first before distribution to the rest of the global community, based on projected number of cases and vulnerability to harm.

Open Access PDF

Concepts Keywords
Global Allocation
Monkeypox Countries
Prioritizing Endemic
Unjust Equitable
Vaccines Exposure
Global
Harm
Harms
Monkeypox
Pepv
Preventing
Priority
Prophylaxis
Spread
Vaccines

Semantics

Type Source Name
disease MESH monkeypox
disease MESH infection
drug DRUGBANK Aspartame
disease VO vaccine
disease VO USA
disease VO Canada
disease VO organization
disease MESH death
disease MESH complications
disease MESH smallpox
disease VO MVA
disease VO ACAM2000
disease VO Vaccinia virus
disease MESH myocarditis
disease VO vaccination
drug DRUGBANK Coenzyme M
disease MESH COVID 19 pandemic
disease IDO country
drug DRUGBANK Tropicamide
disease VO Equity
disease VO dose
disease MESH malnutrition
disease VO viable
disease VO effectiveness
disease IDO production
disease MESH rabies
disease VO time
disease VO population
disease MESH emergency
drug DRUGBANK Ribostamycin
disease VO Monkeypox virus
disease VO intradermal vaccination
disease VO immunization
disease VO smallpox vaccine
disease VO influenza vaccines
disease MESH avian influenza
disease MESH influenza

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *